Literature DB >> 9234917

Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy.

J O Schorge1, K L Molpus, D Koelliker, N Nikrui, A Goodman, A F Fuller.   

Abstract

The records of 171 patients with lymph node-negative stage IB and IIA cervical cancer primarily treated with radical hysterectomy and pelvic lymphadenectomy from 1974 to 1992 were retrospectively reviewed to identify poor prognostic factors and evaluate the role of adjuvant pelvic radiotherapy. One hundred sixteen patients (68%) were treated with radical hysterectomy alone (RH) and 55 patients (32%) received adjuvant radiotherapy (RH + RT). Factors predictive of recurrence for the entire group of patients included lymph-vascular space invasion (LVSI) (P = 0.003) and grade 3 histology (P = 0.04). Patients receiving RH + RT were older and more likely to have outer third cervical wall invasion, LVSI, positive margins, > or =2 cm pathologic tumor size, and >4 cm clinical tumor size (all P < 0.05). Overall, 28 patients (16%) developed recurrent disease with no difference between RH and RH + RT groups. After controlling for confounding variables, patients with LVSI who received RH + RT were less likely to develop disease recurrence than patients receiving RH alone (P = 0.04). LVSI is an important prognostic variable in lymph node-negative stage IB and IIA cervical cancer. Although adjuvant pelvic radiotherapy may decrease the risk of recurrence in patients with LVSI, the majority of patients with negative lymph nodes may be treated with radical surgery alone.

Entities:  

Mesh:

Year:  1997        PMID: 9234917     DOI: 10.1006/gyno.1997.4691

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  [Cervix carcinoma, stage IB and IIA without lymph node involvement: the role of adjuvant radiotherapy after radical hysterectomy].

Authors:  R Biener; A Atzinger
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

2.  Risk factors for lower-limb lymphedema after surgery for cervical cancer.

Authors:  Yoko Ohba; Yukiharu Todo; Noriko Kobayashi; Masanori Kaneuchi; Hidemichi Watari; Mahito Takeda; Satoko Sudo; Masataka Kudo; Hidenori Kato; Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2011-01-07       Impact factor: 3.402

3.  A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery.

Authors:  Juan Pu; Shan-shan Qin; Jin-xia Ding; Yan Zhang; Wei-guo Zhu; Chang-hua Yu; Tao Li; Guang-zhou Tao; Fu-zhi Ji; Xi-lei Zhou; Ji-hua Han; Ya-lin Ji; Jun-xia Sun
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-18       Impact factor: 4.553

4.  Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.

Authors:  Alfonso Ferrara; Marion Nonn; Peter Sehr; Carola Schreckenberger; Michael Pawlita; Matthias Dürst; Achim Schneider; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-30       Impact factor: 4.553

Review 5.  Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.

Authors:  David Cibula; Nadeem R Abu-Rustum; Daniela Fischerova; Selvan Pather; Katie Lavigne; Jiri Slama; Kaled Alektiar; Lin Ming-Yin; Roman Kocian; Anna Germanova; Filip Frühauf; Lukas Dostalek; Ladislav Dusek; Kailash Narayan
Journal:  Gynecol Oncol       Date:  2018-10-20       Impact factor: 5.482

6.  Two cases of endocervical villoglandular adenocarcinoma: Support for conservative management.

Authors:  Sarah Dilley; Colin Newbill; Tanja Pejovic; Elizabeth Munro
Journal:  Gynecol Oncol Rep       Date:  2015-02-27

7.  Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer.

Authors:  Sunghoon Kim; Hye Won Chung; Kyoung-Ryul Lee; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2014-08-21       Impact factor: 5.531

8.  Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.

Authors:  Sunghoon Kim; Hye Won Chung; Hoon Young Kong; Jong Baeck Lim
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

9.  Preoperative CA125 and fibrinogen in patients with endometrial cancer: a risk model for predicting lymphovascular space invasion.

Authors:  Xingchen Zhou; Husheng Wang; Xipeng Wang
Journal:  J Gynecol Oncol       Date:  2016-10-27       Impact factor: 4.401

10.  Risk strata-based therapy and outcome in stage Ib-IIa carcinoma cervix: single-centre ten-year experience.

Authors:  Rajshekar S Kundargi; B Guruprasad; Praveen Shankar Rathod; Pn Shakuntala; K Shobha; Vr Pallavi; K Uma Devi; Ud Bafna
Journal:  Ecancermedicalscience       Date:  2013-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.